GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » Equity-to-Asset

Biotricity (Biotricity) Equity-to-Asset : -4.87 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biotricity Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biotricity's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-26.73 Mil. Biotricity's Total Assets for the quarter that ended in Dec. 2023 was $5.49 Mil. Therefore, Biotricity's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -4.87.

The historical rank and industry rank for Biotricity's Equity-to-Asset or its related term are showing as below:

BTCY' s Equity-to-Asset Range Over the Past 10 Years
Min: -59.84   Med: -3.05   Max: 0.76
Current: -4.87

During the past 10 years, the highest Equity to Asset Ratio of Biotricity was 0.76. The lowest was -59.84. And the median was -3.05.

BTCY's Equity-to-Asset is ranked worse than
97.94% of 872 companies
in the Medical Devices & Instruments industry
Industry Median: 0.645 vs BTCY: -4.87

Biotricity Equity-to-Asset Historical Data

The historical data trend for Biotricity's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity Equity-to-Asset Chart

Biotricity Annual Data
Trend Aug14 Aug15 Dec16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.62 -1.50 -1.54 -0.13 -3.05

Biotricity Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.33 -3.05 -3.81 -3.73 -4.87

Competitive Comparison of Biotricity's Equity-to-Asset

For the Medical Devices subindustry, Biotricity's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotricity's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Biotricity's Equity-to-Asset falls into.



Biotricity Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Biotricity's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=-19.845/6.511
=-3.05

Biotricity's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-26.727/5.486
=-4.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotricity  (NAS:BTCY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Biotricity Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Biotricity's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotricity (Biotricity) Business Description

Traded in Other Exchanges
Address
275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.
Executives
Chester P White director 447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon director 1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq director, 10 percent owner, officer: CEO and Chairman of the Board C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou officer: Chief Financial Officer C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065

Biotricity (Biotricity) Headlines

From GuruFocus